This novel vaccine is comprised of inactivated whole tumor cells that lack the CD47 protein, making them more susceptible to immune cells in the body

About

This invention uses human genome editing to convert cancer cells into therapeutic cancer vaccines. The introduction of these genome edited tumor cells into patients will trigger the body’s immune system to recognize and attack cancer cells, leading a significant reduction of cancerous cells. This new cancer therapy could potentially save millions of lives.

Key Benefits

It does not require the delivery of antibodies or DNA plasmids to tumors, which is less efficient than this technology usually hard to achieve. Genome deletion of CD47 removes the protection of cancer cells from being recognized by macrophages; thus, it elicits much higher level of immunogenicity after administration compared to the use of dead unmodified cancer cells. It uses patients' own cells, eliminating the problem of immune rejection. It is efficient against metastatic cancer cells.

Register for free for full unlimited access to all innovation profiles on LEO

  • Discover articles from some of the world’s brightest minds, or share your thoughts and add one yourself
  • Connect with like-minded individuals and forge valuable relationships and collaboration partners
  • Innovate together, promote your expertise, or showcase your innovations